There are currently 334 clinical trials in Norfolk, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Hospital of The King's Daughters, Sentara Norfolk General Hospital, Virginia Oncology Associates and Eastern Virginia Medical School. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Kidney Tumors in Younger Patients
Recruiting
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
Gender:
All
Ages:
29 years and below
Trial Updated:
09/06/2023
Locations: Children's Hospital of The King's Daughters, Norfolk, Virginia
Conditions: Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Recruiting
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body,... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
08/24/2023
Locations: Children's Hospital of The King's Daughters, Norfolk, Virginia
Conditions: Langerhans Cell Histiocytosis
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
Recruiting
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for up to 14 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
08/23/2023
Locations: Sentara Norfolk General Hospital, Norfolk, Virginia
Conditions: Thrombosis, Deep Vein, Iliofemoral; Thrombosis
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Recruiting
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, b... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
08/17/2023
Locations: Wagner Macula & Retina Center, Norfolk, Virginia
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children
Recruiting
The main aims of the study are to check the side effects and effectiveness of Dexlansoprazole in healing erosive esophagitis (EE) side effects and effectiveness of Dexlansoprazole in maintaining healed EE in children. Participants will take Dexlansoprazole by mouth.
Gender:
All
Ages:
Between 2 years and 11 years
Trial Updated:
08/16/2023
Locations: The Children's Hospital of The King's Daughters, Norfolk, Virginia
Conditions: Erosive Esophagitis
A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception
Recruiting
This is a Phase I multicenter, open-label, dose-ranging, three-dose PK and PD study of injectable LB administered as an IM or SQ injection at 40 mg, and subsequently at 50mg SQ and then 60 mg SQ depending on the preliminary pharmacokinetic and pharmacodynamic results obtained with 40 mg dosing.
Gender:
Female
Ages:
Between 18 years and 40 years
Trial Updated:
08/11/2023
Locations: Eastern Virginia Medical School, Norfolk, Virginia
Conditions: Healthy Women, Female Contraception
Study Comparing Ultrasound-guided FICNB Block to Systemic Analgesia in Treatment of Pediatric Femur Fracture
Recruiting
The goal of this prospective observational study is to compare pain control strategies in children with femur fractures. Researchers will compare ultrasound-guided fascia iliaca compartment nerve block to IV pain control alone. The main questions it aims to answer are: Are ultrasound-guided fascia iliaca compartment nerve blocks as effective as IV pain control in controlling pain? Do patients who receive an ultrasound-guided fascia iliaca compartment nerve block require less opioid pain medicat... Read More
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
07/12/2023
Locations: Children's Hospital of the King's Daughters, Norfolk, Virginia
Conditions: Femur Fracture
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
Recruiting
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The CAS test is an adjunct to other diagnostic evaluations, and is indicated for use with the Optina Diagnostics' MHRC (K200254).
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
07/07/2023
Locations: East Virginia Medical School (EVMS), Norfolk, Virginia
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Recruiting
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
Gender:
Female
Ages:
Between 45 years and 74 years
Trial Updated:
06/21/2023
Locations: Sentara Leigh Hospital, Norfolk, Virginia +1 locations
Conditions: Breast Screening
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Virginia Oncology Associates - Lake Wright, Norfolk, Virginia +1 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
Recruiting
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
Gender:
All
Ages:
Between 1 month and 18 years
Trial Updated:
06/19/2023
Locations: Children's Specialty Group, Norfolk, Virginia
Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Terumo Aortic Global Endovascular Registry
Recruiting
Multi-arm, multi-center, open label, prospective observational registry designed to obtain safety and performance data on the use of CE marked and custom Terumo Aortic endovascular grafts.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2023
Locations: Sentara Heart Hospital, Norfolk, Virginia
Conditions: Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery